PAIN
Volume 114, Issue 1 , Pages 212-220 , March 2005

Inhibitors of serine/threonine protein phosphatases antagonize the antinociception induced by agonists of α2 adrenoceptors and GABAB but not κ-opioid receptors in the tail flick test in mice

Received 22 September 2004 ,Revised 1 December 2004 ,Accepted 13 December 2004.

References 

  1. Alcántara-Hernández R, Vázquez-Prado J, García-Sáinz JA. Protein phosphatase–protein kinase interplay modulates α1b-adrenoceptor phosphorylation: effects of okadaic acid. Br J Pharmacol. 2000;129:727–730
  2. Ansonoff MA, Etgen AM. Receptor phosphorylation mediates estradiol reduction of alpha2-adrenoceptor coupling to G protein in the hypothalamus of female rats. Endocrine. 2001;14:165–174
  3. Assari T, Cox S, Munday MR, Pearce B. Regulation of α1-adrenoceptor-linked phosphoinositide metabolism in cultured glia: involvement of protein phosphatases and kinases. Cell Signal. 2003;15:403–412
  4. Bernstein MA, Welch SP. Inhibition of protein phosphatases alters the expression of morphine tolerance in mice. Eur J Pharmacol. 1998;341:173–177
  5. Bialojan C, Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J. 1988;256:283–290
  6. Bowery NG. GABAB receptor pharmacology. Annu Rev Pharmacol Toxicol. 1993;33:109–147
  7. Bushfield M, Lavan BE, Houslay M. Okadaic acid identifies a phosphorylation/dephosphorylation cycle controlling the inhibitory guanine-nucleotide-binding regulatory protein Gi2. Biochem J. 1991;274:317–321
  8. Chan SF, Sucher NJ. An NMDA receptor signalling complex with protein phosphatase 2A. J Neurosci. 2001;21:7985–7992
  9. Chen MX, McPartlin AE, Brown L, Chen YH, Barker HM, Cohen PT. A novel human protein serine/threonine phosphatase, which possesses four tetratricopeptide repeat motifs and localizes to the nucleus. Eur Mol Biol Org J. 1994;13:4278–4280
  10. Chik CL, Li B, Karpinski E, Ho AK. Regulation of the L-type Ca2+ channel current in rat pinealocytes: role of basal phosphorylation. J Neurochem. 1999;72:73–80
  11. Cohen PTW, Klumpp S, Schelling DL. An improved procedure for identifying and quantitating protein phosphatases in mammalian tissues. Fed Eur Biochem Soc Lett. 1989;250:596–600
  12. Cohen P, Holmes CF, Tsukitani Y. Okadaic acid: a new probe for the study of cellular regulation. Trends Biochem Sci. 1990;15:98–102
  13. Davare MA, Horne MC, Hell JW. Protein phosphatase 2A is associated with class C L-type calcium channels (Cav1.2) and antagonizes channel phosphorylation by cAMP-dependent protein kinase. J Biol Chem. 2000;275:39710–39717
  14. Del Pozo E, Ruiz-Garcia C, Baeyens JM. Analgesic effects of diltiazem and verapamil after central and peripheral administration in the hot-plate test. Gen Pharmacol. 1990;21:681–685
  15. Dierssen M, Florez J, Hurle MA. Calcium channel modulation by dihydropyridines modifies sufentanil-induced antinociception in acute and tolerant conditions. Naunyn Schmiedeberg's Arch Pharmacol. 1990;342:559–565
  16. Dogrul A, Yesilyurt O, Isimer A, Guzeldemir ME. L-type and T-type calcium channel blockade potentiate the analgesic effects of morphine and selective μ opioid agonist, but not to selective δ and κ agonist at the level of the spinal cord in mice. Pain. 2001;93:61–68
  17. Firth TA, Mawe GM, Nelson MT. Pharmacology and modulation of K(ATP) channels by protein kinase C and phosphatases in gallbladder smooth muscle. Am J Physiol Cell Physiol. 2000;278:C1031–C1037
  18. Foster JD, Pananusorn B, Cervinski MA, Holden HE, Vaughan RA. Dopamine transporters are dephosphorylated in striatal homogenates and in vitro by protein phosphatase 1. Brain Res Mol Brain Res. 2003;110:100–108
  19. Garzón J, Rodríguez-Díaz M, DeAntonio I, DeFelipe J, Rodríguez J-R, Sánchez-Blázquez P. Myr+-Gi2α and Goα subunits restore the efficacy of opioids, clonidine and neurotensin giving rise to antinociception in G-protein knock-down mice. Neuropharmacology. 1999;38:1861–1873
  20. Girault JA. Protein kinases and phosphatases. Neurotransmissions. 1994;10:1–6
  21. Haley TJ, Mccormick WG. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol. 1957;12:12–15
  22. Hastie CJ, Cohen PT. Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters. Fed Eur Biochem Soc Lett. 1998;431:357–361
  23. Hemmings HC, Nairn AC, McGuinness TL, Huganir RL, Greengard P. Role of protein phosphorylation in neuronal signal transduction. Fed Am Soc Exp Biol J. 1989;3:1583–1592
  24. Herzig S, Neumann J. Effects of serine/threonine protein phosphatases on ion channels in excitable membranes. Pharmacol Rev. 2000;80:173–196
  25. Holliday ND, Tough IR, Cox HM. Inhibition of cyclic AMP-dependent chloride secretion by PP receptors and alpha 2-adrenoceptors in a human colonic epithelial cell line. Naunyn-Schmiedeberg's Arch Pharmacol. 1997;355:183–189
  26. Honkanen RE. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. Fed Eur Biochem Soc Lett. 1993;330:283–286
  27. Honkanen RE, Golden T. Regulators of serine/threonine protein phosphatases at the dawn of a clinical era?. Curr Med Chem. 2002;9:2055–2075
  28. Honkanen RE, Codispoti BA, Tse K, Boynton AL. Characterization of natural toxins with inhibitory activity against serine/threonine protein phosphatases. Toxicon. 1994;32:339–350
  29. Huang X, Honkanen RE. Molecular cloning, expression, and characterization of a novel human serine/threonine protein phosphatase, PP7, that is homologous to Drosophila retinal degeneration C gene product (rdgC). J Biol Chem. 1998;273:1462–1468
  30. Lambert NA, Wilson WA. High-threshold Ca2+ currents in rat hippocampal interneurones and their selective inhibition by activation of GABAB receptors. J Physiol. 1996;492:115–127
  31. Li YW, Bayliss DA. Activation of α2-adrenoceptors causes inhibition of calcium channels but does not modulate inwardly-rectifying K+ channels in caudal raphe neurons. Neuroscience. 1998;82:753–765
  32. Li YM, Casida JE. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc Natl Acad Sci. 1992;89:11867–11870
  33. Li YM, MacKintosh C, Casida JE. Protein phosphatase 2A and its [3H]cantharidin/[3H]endothall thioanhydride binding site. Inhibitor specificity of cantharidin and ATP analogues. Biochem Pharmacol. 1993;46:1435–1443
  34. Light PE, Allen BG, Walsh MP, French RJ. Regulation of adenosine triphosphate-sensitive potassium channels from rabbit ventricular myocytes by protein kinase C and type 2A protein phosphatase. Biochemistry. 1995;34:7252–7257
  35. Mitsuhashi S, Matsuura N, Ubukata M, Oikawa H, Shima H, Kikuchi K. Tautomycetin is a novel and specific inhibitor of serine/threonine protein phosphatase type 1, PP1. Biochem Biophys Res Commun. 2001;287:328–331
  36. Moncada A, Cendan CM, Baeyens JM, Del Pozo E. Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice. Eur J Pharmacol. 2003;465:53–60
  37. Mullner C, Yakubovich D, Dessauer CW, Platzer D, Schreibmayer W. Single channel analysis of the regulation of GIRK1/GIRK4 channels by protein phosphorylation. Biophys J. 2003;84:1399–1409
  38. Nishiwaki S, Fujiti H, Suganuma M, Furuya-Suguri H, Matsushima R, Iida Y, et al. Structure–activity relationship within a series of okadaic acid derivatives. Carcinogenesis. 1990;11:1837–1841
  39. Ocaña M, Baeyens JM. Differential effects of K+ channel blockers on antinociception induced by α2-adrenoceptor, GABAB and κ-opioid receptor agonists. Br J Pharmacol. 1993;110:1049–1054
  40. Ocaña M, Del Pozo E, Baeyens JM. ATP-dependent K+ channel blockers antagonize morphine- but not U-504,88H-induced antinociception. Eur J Pharmacol. 1993;230:203–207
  41. Ocaña M, Del Pozo E, Barrios M, Baeyens JM. Subgroups among μ-opioid receptor agonists distinguished by ATP-sensitive K+ channel-acting drugs. Br J Pharmacol. 1995;114:1296–1302
  42. Ocaña M, Barrios M, Baeyens JM. Cromakalim differentially enhances antinociception induced by agonists of Alpha2 Adrenoceptors, γ-Aminobutyric AcidB, Mu and Kappa opioid receptors. J Pharmacol Exp Ther. 1996;276:1136–1142
  43. Ocaña M, Cendán CM, Cobos EJ, Entrena JM, Baeyens JM. Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol. 2004;500:203–219
  44. Odagaki Y, Koyama T. Identification of Gα subtype(s) involved in γ-aminobutyric acidB receptor-mediated high-affinity guanosine triphosphatase activity in rat cerebral cortical membranes. Neurosci Lett. 2001;297:137–141
  45. Parsley S, Gazi L, Bobirnac I, Loetscher E, Schoeffter P. Functional α2C-adrenoceptors in human neuroblastoma SH-SY5Y cells. Eur J Pharmacol. 1999;372:109–111
  46. Picolo G, Cassola AC, Cury Y. Activation of peripheral ATP-sensitive K+ channels mediates the antinociceptive effect of Crotalus durissus terrificus snake venom. Eur J Pharmacol. 2003;469:57–64
  47. Price NE, Mumby MC. Brain protein serine/threonine phosphatases. Curr Opin Neurobiol. 1999;9:336–342
  48. Robles LI, Barrios M, Del Pozo E, Dordal A, Baeyens JM. Effects of K+ channel blockers and openers on antinociception induced by agonists of 5-HT1A receptors. Eur J Pharmacol. 1996;295:181–188
  49. Strassheim D, Malbon CC. Phosphorylation of Giα2 attenuates inhibitory adenylyl cyclase in neuroblastoma/glioma hybrid (NG-10815) cells. J Biol Chem. 1994;269:14307–14313
  50. Strassheim D, Law PY, Loh HH. Contribution of phospholipase C-beta 3 phosphorylation to the rapid attenuation opioid-activated phosphoinositide response. Mol Pharmacol. 1998;53:1047–1053
  51. Surmeier DJ, Bargas J, Hemmings HC, Nairn AC, Greengard P. Modulation of calcium currents by a D1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons. Neuron. 1995;14:385–397
  52. Vázquez-Prado J, Casas-González P, García-Sáinz A. G protein-coupled receptor cross-talk: pivotal roles of protein phosphorylation and protein–protein interactions. Cell Signal. 2003;15:549–557
  53. Walsh AH, Cheng A, Honkanen RE. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. Fed Eur Biochem Soc Lett. 1997;416:230–234
  54. Wang L, Medina VM, Rivera M, Gintzler AR. Relevance of phosphorylation state to opioid responsiveness in opiate naive and tolerant/dependent tissue. Brain Res. 1996;723:61–69
  55. Wei ZY, Roerig SC. Spinal morphine/clonidine antinociceptive synergism is regulated by protein kinase C, but not protein kinase A activity. J Pharmacol Exp Ther. 1998;287:937–943
  56. Welch SP, Dunlow LD. Antinociceptive activity of intrathecally administered potassium channel openers and opioid agonists: a common mechanism of action?. J Pharmacol Exp Ther. 1993;267:399
  57. Zhang X, Wu J, Fang L, Willis WD. The effects of protein phosphatase inhibitors on nociceptive behavioural responses of rats following intradermal injection of capsaicin. Pain. 2003;106:443–451
  58. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983;16:109–110

PII: S0304-3959(04)00587-1

doi: 10.1016/j.pain.2004.12.017

PAIN
Volume 114, Issue 1 , Pages 212-220 , March 2005

Article Tools

* Image Usage & Resolution